Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation

Transplantation Reviews

Volumn 25, Issue 2, 2011, Pages 78-89

  Tönshoff, Burkhard ^a   David Neto, Elias ^b   Ettenger, Robert ^c   Filler, Guido ^d   van Gelder, Teun ^e   Goebel, Jens ^f   Kuypers, Dirk R J ^g   Tsai, Eileen ^c   Vinks, Alexander A ^f,h   Weber, Lutz T ⁱ   Zimmerhackl, Lothar Bernd ^j  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c MATTEL CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j INNSBRUCK MEDICAL UNIVERSITY   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

7 O MYCOPHENOLIC ACID GLUCURONIDE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; CYCLOSPORIN A; DRUG METABOLITE; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ANEMIA; AREA UNDER THE CURVE; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERIC COATED TABLET; ENZYME ACTIVITY; GASTRITIS; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAINTENANCE THERAPY; NAUSEA; NEPHROTOXICITY; PREVALENCE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION;

EID: 79953727826     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2011.01.001     Document Type: Review

References (58)

1. The NAPRTCS 2008 Annual Report Available at:, Accessed June 14, 2010. http://web.emmes.com/study/ped/index.htm.
2. Kuypers D.R., Le Meur Y., Cantarovich M., Tredger M.J., Tett S.E., Cattaneo D., et al. Transplantation Society (TTS) Consensus Group on TDM of MPA. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010, 5:341-358.
3. Kearns G.L., Abdel-Rahman S.M., Alander S.W., Blowey D.L., Leeder J.S., Kauffman R.E. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003, 349:1157-1167.
4. Takahashi H., Ishikawa S., Nomoto S., Nishigaki Y., Ando F., Kashima T., et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 2000, 68:541-555.
5. Marshall J.D., Kearns G.L. Developmental pharmacodynamics of cyclosporine. Clin Pharmacol Ther 1999, 66:66-75.
6. Marshall J., Rodarte A., Blumer J., Khoo K.C., Akbari B., Kearns G.L. Pediatric pharmacodynamics of midazolam oral syrup. J Clin Pharmacol 2000, 40:578-589.
7. deWildt S.N., Kearns G.L., Sie S.D., Hop W.C.J., van den Anker J.N. Pharmacodynamics of intravenous and oral midazolam in preterm infants. Clin Drug Invest 2003, 23:27-38.
8. Strassburg C.P., Strassburg A., Kneip S., et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002, 50:259-265.
9. Rother A., Glander P., Vitt E., Feneberg R., von Ahsen N., Armstrong V.W., et al. Inosine 5'-monophosphate dehydrogenase (IMPDH) activity in children and adolescents: physiological regulation and response to mycophenolic acid (MPA) therapy. Am J Transplant 2010, 4(Suppl. 10):1031.
10. Fukuda T., Goebel J., Thogersen H., et al. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. J Clin Pharmacol 2010, [Epub ahead of print].
11. Ettenger R., Warshaw B., Mentser M., et al. Mycophenolate mofetil (MMF) in pediatric renal transplantation. Pediatr Nephrol 1996, 10:C39.
12. Weber L.T., Hoecker B., Armstrong V.W., Oellerich M., Tönshoff B. Long-term pharmacokinetics of mycophenolic acid in pediatric renal transplant recipients over 3 years posttransplant. Ther Drug Monit 2008, 30:570-575.
13. Filler G. Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation. Pediatr Transplant 2006, 10:707-711.
14. Weber L.T., Shipkova M., Lamersdorf T., Niedmann P.D., Wiesel M., Mandelbaum A., et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998, 9:1511-1520.
15. Filler G., Zimmering M., Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000, 14:100-104.
16. Höcker B., van Gelder T., Martin-Govantes J., Machado P., Tedesco H., Rubik J., et al. On behalf of the FDCC Study Group. Comparison of MMF efficacy and safety in paediatric vs. adult renal transplantation: subgroup analysis of the randomised, multicentre FDCC trial. Nephrol Dial Transplant 2010, [Epub ahead of print].
17. Bullingham R., Nicholls A.J., Kamm B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998, 64:429-455.
18. Shipkova M., Armstrong V.W., Oellerich M., Wieland E. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol 2005, 1:505-526.
19. Filler G., Lampe D., Mai I., Strehlau J., Ehrich J.H. Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts. Transpl Int 1998, 11(Suppl 1):S82-S85.
20. Cheam H., Bhakta N., Sievers T., Holt C., Holloway M., Okimoto S., et al. Preliminary results from a randomized controlled trial to evaluate the effect of corticosteroids on tacrolimus and mycophenolate mofetil pharmacokinetics: a mechanistic study as part of the CCTPT SNS 01 Trial 2007.
21. Weber L.T., Shipkova M., Armstrong V.W., Wagner N., Schütz E., Mehls O., et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002, 13:759-768.
22. Weber L.T., Lamersdorf T., Shipkova M., Niedmann P.D., Wiesel M., Zimmerhackl L.B., et al. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation; a longitudinal study in pediatric patients. Ther Drug Monit 1999, 21:498-506.
23. Schuetz E.G., Hazelton G.A., Hall J., Watkins P.B., Klaassen C.D., Guzelian P.S. Induction of digitoxigenin monodigitoxoside UDP-glucuronosyltransferase activity by glucocorticoids and other inducers of cytochrome P-450p in primary monolayer cultures of adult rat hepatocytes and in human liver. J Biol Chem 1986, 261:8270-8275.
24. Cattaneo D., Perico N., Gaspari F., Gotti E., Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002, 62:1060-1067.
25. Hesselink D.A., van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther 2005, 78:317-321.
26. Weber L.T., Hoecker B., Armstrong V.W., Oellerich M., Toenshoff B. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients. Ther Drug Monit 2006, 28:623-631.
27. Weber L.T., Schütz E., Lamersdorf T., Shipkova M., Niedmann P.D., Oellerich M., et al. Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in paediatric renal transplant recipients. The German Study Group on Mycophenolate Mofetil (MMF) Therapy. Nephrol Dial Transplant 1999, 14(Suppl 4):34-35.
28. Schütz E., Armstrong V.W., Shipkova M., Weber L., Niedmann P.D., Lammersdorf T., et al. Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients. Transplant Proc 1998, 30:1182-1184.
29. Filler G., Feber J., Lepage N., Weiler G., Mai I. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant 2002, 6:411-418.
30. David-Neto E., Pereira Araujo L.M., Sumita N.M., Mendes M.E., Ribeiro Castro M.C., Alves C.F., et al. Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. Pediatr Nephrol 2003, 18:266-272.
31. Filler G., Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 2000, 22:169-173.
32. Filler G. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy. Transpl Int 2004, 17:120-125.
33. Shaw L.M., Nawrocki A., Korecka M., Solari S., Kang J. Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations. Ther Drug Monit 2004, 26:347-351.
34. Van Gelder T., Hilbrands L.B., Vanrenterghem Y., Weimar W., de Fijter J.W., Squifflet J.P., et al. A randomized double-blind, multi-center plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplant 1999, 68:261-266.
35. Van Gelder T., Le Meur Y., Shaw L.M., Oellerich M., DeNofrio D., Holt C., et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006, 28:145-154.
36. David-Neto E., Pereira L.M., Kakehashi E., Sumita N.M., Mendes M.E., Castro M.C., et al. The need of mycophenolic acid monitoring in long-term renal transplants. Clin Transplant 2005, 19:19-25.
37. Le Meur Y., Buchler M., Thierry A., et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient out-comes after renal transplantation. Am J Transplant 2007, 7:2496-2503.
38. Prémaud A., Weber L.T., Tönshoff B., et al. Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches. Pharmacol Res 2010, [Epub ahead of print].
39. Weber L.T., Shipkova M., Armstrong V.W., et al. Comparison of the EMIT immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 2002, 48:517-525.
40. Ettenger R., Cohen A., Nast C., Moulton L., Marik J., Gales B. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation. Transplant Proc 1997, 29:340-341.
41. Benfield M.R., Symons J.M., Bynon S., Eckhoff D., Herrin J., Harmon W., et al. Mycophenolate mofetil in pediatric renal transplantation. Pediatr Transplant 1999, 3:33-37.
42. Bunchman T., Navarro M., Broyer M., Sherbotie J., Chavers B., Tönshoff B., et al. The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. Pediatr Nephrol 2001, 16:978-984.
43. Höcker B., Weber L.T., Bunchman T., Rashford M., Tönshoff B. Tricontinental MMF Suspension Study Group. Mycophenolate mofetil suspension in pediatric renal transplantation: three-year data from the tricontinental trial. Pediatr Transplant 2005, 9:504-511.
44. Staskewitz A., Kirste G., Tönshoff B., Weber L.T., Böswald M., Burghard R., et al. Mycophenolate mofetil in pediatric renal transplantation without induction therapy: results after 12 months of treatment. German Pediatric Renal Transplantation Study Group. Transplantation 2001, 71:638-644.
45. Jungraithmayr T., Staskewitz A., Kirste G., Böswald M., Bulla M., Burghard R., et al. German Pediatric Renal Transplantation Study Group. Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years. Transplant 2003, 75:454-461.
46. Cransberg K., Marlies Cornelissen E.A., Davin J.C., Van Hoeck K.J., Lilien M.R., Stijnen T., et al. Improved outcome of pediatric kidney transplantations in the Netherlands-effect of the introduction of mycophenolate mofetil?. Pediatr Transplant 2005, 9:104-111.
47. Ferraris J.R., Ghezzi L.F., Vallejo G., Piantanida J.J., Araujo J.L., Sojo E.T. Improved long-term allograft function in pediatric renal transplantation with mycophenolate mofetil. Pediatr Transplant 2005, 9:178-182.
48. Ettenger R., Sarwal M. Mycophenolate mofetil in pediatric renal transplantation. Transplantation 2005, 80:201-210.
49. Jungraithmayr T.C., Wiesmayr S., Staskewitz A., Kirste G., Bulla M., Fehrenbach H., et al. German Pediatric Renal Transplantation Study Group. Five-year outcome in pediatric patients with mycophenolate mofetil-based renal transplantation. Transplantation 2007, 83:900-905.
50. Ferraris J.R., Tambutti M.L., Prigoshin N., Grosman M., Cardoni R.L. Conversion from mycophenolate mofetil to delayed formulation in pediatric renal transplantation: higher mycophenolic acid predose level but no changes in the immune biomarkers. Pediatr Transplant 2009, 13:731-736.
51. Pape L., Ahlenstiel T., Kreuzer M., Ehrich J.H. Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children. Pediatr Transplant 2008, 12:640-642.
52. Johnson J.A., Gjertson D.W., Ettenger R.B., Tsai E.W. Increase incidence of acute cellular rejection in pediatric renal transplant patients receiving steroid free immune suppression and suboptimal mycophenolate mofetil 2008, Annual Meeting of the American Society of Nephrology, Philadelphia (Pa).
53. Budde K., Bauer S., Hambach P., Hahn U., Roeblitz H., Mai I., et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007, 7:888-898.
54. Cattaneo D., Cortinovis M., Baldelli S., Bitto A., Gotti E., Remuzzi G., et al. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. Clin J Am Soc Nephrol 2007, 2:1147-1155.
55. Filler G., Sharma A.P., Levy D.M., Yasin A. Random pharmacokinetic profiles of EC-MPS in children with autoimmune disease. Pediatr Rheumatol Online J 2010, 8:1.
56. Ettenger R., Bartosh S., Choi L., Zhu W., Niederberger W., Campestrini J., et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatr Transplant 2005, 9:780-787.
57. Meneses Rde P., Kotsifas C.H. Benefits of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in pediatric renal transplant patients with stable graft function. Pediatr Transplant 2009, 13:188-193.
58. Tett S.E., Saint-Marcoux F., Staatz C.E., et al. Mycophenolate-clinical pharmacokinetics, including effects of formulation and different methods of measuring exposure. Transplant Rev 2010, (Orlando), Dec 27. [Epub ahead of print].